Technical analysis of Lipocine Inc. (LPCN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Lipocine Inc. is a biopharmaceutical firm currently in the clinical development phase, concentrating its efforts on creating medicinal products to address a range of neuroendocrine and metabolic conditions. A core aspect of the company's research and development involves formulating oral delivery methods for pharmaceutical compounds that typically suffer from low bioavailability. Its foremost investigational therapy is TLANDO, an oral solution for testosterone replacement.
Price Performance
| 1 month | +5.88% |
| 3 months | -7.30% |
| Year-to-date | -73.10% |
| 1 year | -24.21% |
| 3 years | -37.39% |
| 5 years | -89.05% |
52-Week Range
| 52-week High | $12.37 |
| 52-week Low | $1.81 |
| Avg Volume (90d) | 63K |
Technical Indicators
| SMA 50 | $2.20 |
| SMA 200 | $4.47 |
| Beta | 1.09 |
| 30-day Volatility (annualised) | 35.3% |
| Price vs SMA 50 | -1.7% |
| Price vs SMA 200 | -51.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.66 | |
| 2025-11 | $3.44 | +29.3% |
| 2025-12 | $8.03 | +133.4% |
| 2026-01 | $9.00 | +12.1% |
| 2026-02 | $9.96 | +10.7% |
| 2026-03 | $7.99 | -19.8% |
| 2026-04 | $2.33 | -70.8% |
| 2026-05 | $2.25 | -3.4% |
| 2026-06 | $2.56 | +13.8% |
| 2026-07 | $2.12 | -17.2% |
| 2026-08 | $2.24 | +5.7% |
| 2026-09 | $2.16 | -3.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $2.16 |
| Market Cap | $18M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.79 |
| EV / EBITDA | -1.23 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 11.48 |